Practical problems and resource implications with the use of warfarin for venous thromboembolism in patients with cancer
PG Morris, C Davenport, D O'dwyer… - Irish Journal of Medical …, 2007 - Springer
PG Morris, C Davenport, D O'dwyer, C O'callaghan, OS Breathnach, L Grogan
Irish Journal of Medical Science, 2007•SpringerBackground Oral anticoagulants present multiple practical problems for patients undergoing
chemotherapy. To assess the practice implications of anticoagulation therapy, a review was
carried out. Methods A review of all patients with cancer treated with warfarin for venous
thromboembolism (VTE) over a 1-year-period was carried out. Adverse events and
therapeutic efficacy were assessed and the extra volume of work involved in monitoring was
quantified. Results Fifty-five patients with cancer and VTE were treated with warfarin from …
chemotherapy. To assess the practice implications of anticoagulation therapy, a review was
carried out. Methods A review of all patients with cancer treated with warfarin for venous
thromboembolism (VTE) over a 1-year-period was carried out. Adverse events and
therapeutic efficacy were assessed and the extra volume of work involved in monitoring was
quantified. Results Fifty-five patients with cancer and VTE were treated with warfarin from …
Background
Oral anticoagulants present multiple practical problems for patients undergoing chemotherapy. To assess the practice implications of anticoagulation therapy, a review was carried out.
Methods
A review of all patients with cancer treated with warfarin for venous thromboembolism (VTE) over a 1-year-period was carried out. Adverse events and therapeutic efficacy were assessed and the extra volume of work involved in monitoring was quantified.
Results
Fifty-five patients with cancer and VTE were treated with warfarin from 07/04 to 06/05. Twenty-one invasive interventions required disruption of anticoagulation. There were eight admissions for haemorrhage. Nine patients died while on warfarin. A total of 1,379 coagulation tests were performed. There were 382 extra dayward visits attributable to warfarin monitoring. On treatment, 13 patients (24%) were changed from warfarin therapy to low molecular weight heparin (LMWH).
Conclusions
This study identifies and quantifies the extra resource utilization with warfarin therapy in patients undergoing chemotherapy.
Springer
